The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth rate (AGR) of 0.90 per cent from 2.00 million in 2023 to 2.18 million in 2033 ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 7 and set a price target of $10.00.

Gilead Sciences (GILD) ended the recent trading session at $89.14, demonstrating a -1.64% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of ...

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

This was the stock's fifth consecutive day of losses.

The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over these assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic ...